ev3 Inc

ev3 — Q1 2009 Earnings Presentation

13 slides from ev3's earnings presentation, Apr 28, 2009

  1. Slide 1: Q1 '09 Highlights

    Q1 '09 Highlights April 28, 2009

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "estimat

  3. Slide 3: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation, including "non- GAAP net sales on a constant currency basis," "non-GAAP legacy peripheral vascular net sales," "non-GAAP net sales by geography on a constant currency basis," "non- GAAP adjusted net

  4. Slide 4: Q1 '09 Financial Summary

    Q1 '09 Financial Summary Net product sales of $100.4 million +6% vs. Q1 2008; +10% constant currency* Peripheral vascular sales, excluding atherectomy*, +16% vs. Q1 2008; +20% constant currency* Peripheral stents +17% vs. Q1 2008; +22% constant currency* Neurovascular sales +11% vs. Q1 2008; +18% co

  5. Slide 5: Actual Results vs. Last Quarter & Year Ago

    Actual Results vs. Last Quarter & Year Ago *Constant Currency; For reconciliations, see our website at www.ev3.net. **All quarters presented are adjusted for amortization and non-cash stock-based compensation. Q1 2009 is also adjusted for a non- cash FoxHollow lease reserve adjustment and a realized

  6. Slide 6: Total Q1 '09 Product Revenue Growth of 10%*

    Total Q1 '09 Product Revenue Growth of 10%* Q2 Q3 Q4 Q1 Q1 East 101.5 100 105.6 95.1 100.4 Total Worldwide Product Sales ($M) Q2 Q3 Q4 Q1 Q1 East 35.9 36.6 39.4 34.8 38.7 Total International ($M) +24%* Q2 Q3 Q4 Q1 Q1 East 70.8 66.9 68.1 64.1 66.2 Worldwide Peripheral Vascular ($M) +7%* Q2 Q3 Q4 Q1 Q

  7. Slide 7: Third consecutive quarter of cash and cash equivalents growth

    Q1 08 Q2 08 Q3 08 Q4 08 Q1 09 East 57 38.7 45.9 59.7 66.9 Third consecutive quarter of cash and cash equivalents growth Cash / Cash Equivalents Cash/cash equivalents increased $7.3M Q1 '09 vs Q4 '08 Inventory days down 29% in Q1 '09 vs Q1 '08 Total debt decreased to $8.3M 7

  8. Slide 8: Financial Summary: Continuing to Improve Performance

    Financial Summary: Continuing to Improve Performance Net Product Sales* $95,050 $101,509 $100,018 $105,656 $100,395 Gross Profit $67,639 $71,528 $68,747 $71,316 $69,407 Gross Margin 66.8% 66.4% 64.2% 67.2% 69.1% Net Loss $(9,770) $(27,422) $(7,310) $(291,120) $(1,809) Adjusted net EPS (loss) per dil

  9. Slide 9: Guidance - As of April 28, 2009

    Guidance - As of April 28, 2009 Expect Full-Year 2009 Positive GAAP EPS Revenues: Q2 2009: $102 to $106 million Full-Year 2009: $420 to $430 million Adjusted EPS (loss)1 per diluted share: Q2 2009: $0.06 to $0.091,2 Full-Year 2009: $0.40 to $0.451,2 Adjusted EPS (loss) guidance is based on weighted

  10. Slide 10: Business Model Structure - Select P&L Information

    2008 % of sales 2007 2009 Goal Business Model Structure - Select P&L Information Sales 100% 100% 100% Gross margin 66% 65% 70% Selling, general & administrative 55% 69% 49% Taxes 0.4% 0.3% 1% Research & development 12% 17% 12% Stock-based comp & amortization 11% 11% 9% Adjusted net income (loss)* 2.

  11. Slide 11: Continue to Stay Focused on Pathway to Profitable Growth

    Continue to Stay Focused on Pathway to Profitable Growth Long-term profitable revenue growth Improve cost structure Increase sales force productivity Grow international sales Clinical evidence New products 1 2 3 4 5

  12. Slide 12: Why Invest in ev3

    Why Invest in ev3 I N S U M M A R Y 12 Broadest product offering in $2B growing global market largest pure-play in endovascular market Clear roadmap for sustained, profitable growth improved costs, productivity, clinical evidence, new products Company focused to achieve future profitability "vital f

  13. Slide 13: Q1 '09 Highlights

    Q1 '09 Highlights April 28, 2009

ev3 — Q1 2009 Earnings Presentation on 6ix